Abstract: A method of treating a degenerative bone condition of a subject includes administering to hematopoietic progenitor cells or osteoclast progenitor cells of the subject at least one agent that substantially reduces the interaction of at least one of C3a or C5a with the C3a receptor (C3aR) and/or C5a receptor (C5aR), a STAT3/IL-6 signaling pathway antagonist, and a combination thereof, the agent being administered to the hematopoietic progenitor cells or osteoclast progenitor cells at an amount effective to inhibit osteoclast differentiation of hematopoietic progenitor cells or osteoclast progenitor cells.

Abstract: In certain aspects, the invention relates to cell delivery compositions comprising a chondrogenic cell and a targeting moiety. Such compositions may be used, for example, in administering a targeted cell therapy to a subject.

Abstract: A method of treating a degenerative bone condition of a subject includes administering to hematopoietic progenitor cells or osteoclast progenitor cells of the subject at least one agent that substantially reduces the interaction of at least one of C3a or C5a with the C3a receptor (C3aR) and/or C5a receptor (C5aR), a STAT3/IL-6 signaling pathway antagonist, and a combination thereof, the agent being administered to the hematopoietic progenitor cells or osteoclast progenitor cells at an amount effective to inhibit osteoclast differentiation of hematopoietic progenitor cells or osteoclast progenitor cells.

Abstract: A method of treating a lymphocyte mediated inflammation in a subject including administering a therapeutically effective amount of a cell delivery composition to the subject, the cell delivery composition of the application including an immunosuppressive cell and a plurality of targeting moieties that bind to endothelial cell adhesion molecules expressed by endothelial cells as a result of a lymphocyte mediated inflammatory response in the subject, the targeting moieties coated on and linked to the immunosuppressive cell and enhancing adherence of the immunosuppressive cell to an endothelial cell at a site of lymphocyte mediated inflammation when administered to the subject systemically, wherein the cell delivery composition, suppresses lymphocyte mediated inflammation in the subject.

Abstract: A method of treating a lymphocyte mediated inflammation in a subject including administering a therapeutically effective amount of a cell delivery composition to the subject, the cell delivery composition of the application including an immunosuppressive cell and a plurality of targeting moieties that bind to endothelial cell adhesion molecules expressed by endothelial cells as a result of a lymphocyte mediated inflammatory response in the subject, the targeting moieties coated on and linked to the immunosuppressive cell and enhancing adherence of the immunosuppressive cell to an endothelial cell at a site of lymphocyte mediated inflammation when administered to the subject systemically, wherein the cell delivery composition, suppresses lymphocyte mediated inflammation in the subject.

Abstract: A peptide for targeting bone marrow consists of about 5 to about 25 amino acids and includes an amino acid sequence that targets the peptide to bone marrow.

Abstract: A method of treating a degenerative bone condition of a subject includes administering to hematopoietic progenitor cells or osteoclast progenitor cells of the subject at least one agent that substantially reduces the interaction of at least one of C3a or C5a with the C3a receptor (C3aR) and/or C5a receptor (C5aR), a STAT3/IL-6 signaling pathway antagonist, and a combination thereof, the agent being administered to the hematopoietic progenitor cells or osteoclast progenitor cells at an amount effective to inhibit osteoclast differentiation of hematopoietic progenitor cells or osteoclast progenitor cells.

Abstract: A method of treating a lymphocyte mediated inflammation in a subject including administering a therapeutically effective amount of a cell delivery composition to the subject, the cell delivery composition of the application including an immunosuppressive cell and a plurality of targeting moieties that bind to endothelial cell adhesion molecules expressed by endothelial cells as a result of a lymphocyte mediated inflammatory response in the subject, the targeting moieties coated on and linked to the immunosuppressive cell and enhancing adherence of the immunosuppressive cell to an endothelial cell at a site of lymphocyte mediated inflammation when administered to the subject systemically, wherein the cell delivery composition, suppresses lymphocyte mediated inflammation in the subject.

Abstract: A peptide for targeting bone marrow consists of about 5 to about 25 amino acids and includes an amino acid sequence that targets the peptide to bone marrow.

Abstract: A hyaline-like, single layer cartilage tissue construct includes chondrogenic cells dispersed within an endogenously produced extracellular matrix. The single layer cartilage tissue construct has a glycosaminoglycan content substantially equal to the glycosaminoglycan content of native cartilage tissue. A method for generating a single layer cartilage tissue construct includes isolating a population of chondrogenic cells and then expanding the population of chondrogenic cells. Next, the population of chondrogenic cells is seeded into a bioreactor having a volume defined by oppositely disposed gas permeable membranes. The population of chondrogenic cells is then cultured in a serum-free culture medium for a time sufficient to permit the population of chondrogenic cells to differentiate and form the single layer cartilage tissue construct.

Abstract: A bioreactor includes a housing and a support mechanism for suspending the housing above the bottom surface of a culture vessel. The housing includes a member having oppositely disposed first and second surfaces and an inner surface defining an opening. The opening extends between the first and second surfaces of the member. The bioreactor includes a gas and liquid permeable membrane having first and second surfaces attached to the second surface of the member. The first surface of the gas and liquid permeable membrane and the member define a culture space for growing or culturing cells.

Abstract: In certain aspects, the invention relates to cell delivery compositions comprising a progenitor cell and a targeting moiety, and methods related thereto. Such compositions and methods may be used, for example, in administering a targeted cell therapy cell therapy to a subject.

Abstract: In certain aspects, the invention relates to cell delivery compositions comprising a chondrogenic cell and a targeting moiety. Such compositions may be used, for example, in administering a targeted cell therapy to a subject.